Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.

IF 3.3 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY
Susana Hernandez, Esther Conde, Aida Molero, Ana Suarez-Gauthier, Rebeca Martinez, Marta Alonso, Carlos Plaza, Carmen Camacho, Debora Chantada, Laura Juaneda-Magdalena, Enrique Garcia-Toro, Patricia Saiz-Lopez, Federico Rojo, Mar Abad, Valentina Boni, Sofia Del Carmen, Rita Maria Regojo, Marina Esther Sanchez-Frias, Cristina Teixido, Luis Paz-Ares, Fernando Lopez-Rios
{"title":"Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.","authors":"Susana Hernandez, Esther Conde, Aida Molero, Ana Suarez-Gauthier, Rebeca Martinez, Marta Alonso, Carlos Plaza, Carmen Camacho, Debora Chantada, Laura Juaneda-Magdalena, Enrique Garcia-Toro, Patricia Saiz-Lopez, Federico Rojo, Mar Abad, Valentina Boni, Sofia Del Carmen, Rita Maria Regojo, Marina Esther Sanchez-Frias, Cristina Teixido, Luis Paz-Ares, Fernando Lopez-Rios","doi":"10.5858/arpa.2022-0443-OA","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>The neurotrophic tropomyosin receptor kinase (NTRK) family gene rearrangements have been recently incorporated as predictive biomarkers in a \"tumor-agnostic\" manner. However, the identification of these patients is extremely challenging because the overall frequency of NTRK fusions is below 1%. Academic groups and professional organizations have released recommendations on the algorithms to detect NTRK fusions. The European Society for Medical Oncology proposal encourages the use of next-generation sequencing (NGS) if available, or alternatively immunohistochemistry (IHC) could be used for screening with NGS confirmation of all positive IHC results. Other academic groups have included histologic and genomic information in the testing algorithm.</p><p><strong>Objective.—: </strong>To apply some of these triaging strategies for a more efficient identification of NTRK fusions within a single institution, so pathologists can gain practical insight on how to start looking for NTRK fusions.</p><p><strong>Design.—: </strong>A multiparametric strategy combining histologic (secretory carcinomas of the breast and salivary gland; papillary thyroid carcinomas; infantile fibrosarcoma) and genomic (driver-negative non-small cell lung carcinomas, microsatellite instability-high colorectal adenocarcinomas, and wild-type gastrointestinal stromal tumors) triaging was put forward.</p><p><strong>Results.—: </strong>Samples from 323 tumors were stained with the VENTANA pan-TRK EPR17341 Assay as a screening method. All positive IHC cases were simultaneously studied by 2 NGS tests, Oncomine Comprehensive Assay v3 and FoundationOne CDx. With this approach, the detection rate of NTRK fusions was 20 times higher (5.57%) by only screening 323 patients than the largest cohort in the literature (0.30%) comprising several hundred thousand patients.</p><p><strong>Conclusions.—: </strong>Based on our findings, we propose a multiparametric strategy (ie, \"supervised tumor-agnostic approach\") when pathologists start searching for NTRK fusions.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"318-326"},"PeriodicalIF":3.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5858/arpa.2022-0443-OA","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Context.—: The neurotrophic tropomyosin receptor kinase (NTRK) family gene rearrangements have been recently incorporated as predictive biomarkers in a "tumor-agnostic" manner. However, the identification of these patients is extremely challenging because the overall frequency of NTRK fusions is below 1%. Academic groups and professional organizations have released recommendations on the algorithms to detect NTRK fusions. The European Society for Medical Oncology proposal encourages the use of next-generation sequencing (NGS) if available, or alternatively immunohistochemistry (IHC) could be used for screening with NGS confirmation of all positive IHC results. Other academic groups have included histologic and genomic information in the testing algorithm.

Objective.—: To apply some of these triaging strategies for a more efficient identification of NTRK fusions within a single institution, so pathologists can gain practical insight on how to start looking for NTRK fusions.

Design.—: A multiparametric strategy combining histologic (secretory carcinomas of the breast and salivary gland; papillary thyroid carcinomas; infantile fibrosarcoma) and genomic (driver-negative non-small cell lung carcinomas, microsatellite instability-high colorectal adenocarcinomas, and wild-type gastrointestinal stromal tumors) triaging was put forward.

Results.—: Samples from 323 tumors were stained with the VENTANA pan-TRK EPR17341 Assay as a screening method. All positive IHC cases were simultaneously studied by 2 NGS tests, Oncomine Comprehensive Assay v3 and FoundationOne CDx. With this approach, the detection rate of NTRK fusions was 20 times higher (5.57%) by only screening 323 patients than the largest cohort in the literature (0.30%) comprising several hundred thousand patients.

Conclusions.—: Based on our findings, we propose a multiparametric strategy (ie, "supervised tumor-agnostic approach") when pathologists start searching for NTRK fusions.

利用监督肿瘤诊断方法高效识别 NTRK 融合患者
背景神经营养性肌球蛋白受体激酶(NTRK)家族基因重排最近已被纳入 "肿瘤诊断 "的预测性生物标志物。然而,由于 NTRK 融合的总体频率低于 1%,因此识别这些患者极具挑战性。学术团体和专业组织已就检测 NTRK 融合的算法提出了建议。欧洲肿瘤内科学会(European Society for Medical Oncology)的建议鼓励在有条件的情况下使用新一代测序技术(NGS),或者使用免疫组化技术(IHC)进行筛查,并对所有 IHC 阳性结果进行 NGS 确认。其他学术团体已将组织学和基因组信息纳入检测算法:在单个机构内应用这些分流策略更有效地识别 NTRK 融合,使病理学家能够获得关于如何开始寻找 NTRK 融合的实用见解:提出了一种结合组织学(乳腺和唾液腺分泌性癌、甲状腺乳头状癌、幼年纤维肉瘤)和基因组学(驱动因素阴性的非小细胞肺癌、微卫星不稳定性高的结直肠腺癌和野生型胃肠道间质瘤)分选的多参数策略:用 VENTANA pan-TRK EPR17341 检测法对 323 个肿瘤样本进行染色,作为筛选方法。所有 IHC 阳性病例都同时进行了 2 项 NGS 检测:Oncomine Comprehensive Assay v3 和 FoundationOne CDx。采用这种方法,仅筛查 323 例患者,NTRK 融合的检出率(5.57%)就比文献中由数十万例患者组成的最大队列(0.30%)高出 20 倍:基于我们的研究结果,当病理学家开始搜索NTRK融合时,我们提出了一种多参数策略(即 "监督肿瘤诊断方法")。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.20
自引率
2.20%
发文量
369
审稿时长
3-8 weeks
期刊介绍: Welcome to the website of the Archives of Pathology & Laboratory Medicine (APLM). This monthly, peer-reviewed journal of the College of American Pathologists offers global reach and highest measured readership among pathology journals. Published since 1926, ARCHIVES was voted in 2009 the only pathology journal among the top 100 most influential journals of the past 100 years by the BioMedical and Life Sciences Division of the Special Libraries Association. Online access to the full-text and PDF files of APLM articles is free.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书